AUPH

Full House

Aurinia Pharmaceuticals Inc. · Healthcare · Canada · $2.2B cap · $14.5M/day traded

$16.21 +0.0% · close 12 Nov · scored 13 Nov

Full House: Strong business, sensible price, and the market agrees.

96
Score
Get score and insider alerts
Quality
84
Value
60
Momentum
61

As of 13 Nov 2026, the MoatMap Score for Aurinia Pharmaceuticals Inc. (AUPH) is 96/100, ranked against 25,000+ stocks in 38 markets (Quality 84, Value 60, Momentum 61, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
7.2x
peers 19.5x
ROE
61.4%
peers -31.6%
D/E
0.1x
peers 0.1x
Dividend %
—
trailing yield

ABOUT AURINIA PHARMACEUTICALS INC.

Read

Aurinia Pharmaceuticals Inc. is a Canadian pharmaceutical company primarily focused on developing and commercializing therapies for autoimmune diseases. Its competitive moat is centered around LUPKYNIS (voclosporin), a proprietary drug approved for lupus nephritis, addressing a high unmet medical need and offering a significant market opportunity. Aurinia operates as a commercial-stage biotech, dedicated to expanding the market presence of its specialized therapeutic.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue134.0M175.5M235.1M283.1M28.3%321.7M330.2M388.7M17.2%
EPS-0.76-0.540.042.145250.0%2.28———
Shares142.3M143.8M140.9M132.3M-7.0%134.0M———
Debt8.1M97.6M79.4M74.8M109.9%58.7M———
Equity405.4M378.0M377.5M581.3M12.8%————
Op CF-79.5M-33.5M44.4M135.7M205.6%177.2M———
Inv CF-60.6M-6.7M39.3M-32.8M—————
Fin CF2.4M-5.1M-49.1M-106.1M—————
PRICE (1Y) · USD+2.4%
15.716.116.516.917.42 Oct23 Oct12 Nov
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsAverage

Calmer than 62% of stocks we rank over the past year (volatility 35% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$16.21
RSI (14)
42.6
52-Week Range-15.8% from high
Low $13.52High $19.25

SCORE BREAKDOWN

Quality
84
ROIC
25.0%93.6
ROE
61.4%98.2
GP/Assets
32.4%68.5
Op. Margin
42.3%96.9
FCF/Assets
18.0%95.2
Piotroski
784.1
Int. Cover
40.1x77.3
D/E Ratio
0.09x63.7
Current Ratio
6.12x77.8
Value
60
P/E (TTM)
7.2x93.8
EV/EBITDA
9.6x68.6
P/FCF
16.6x65.6
P/B
3.4x37.3
P/S
6.9x31.0
Div Yield
—N/A
Momentum
61
52W High %
84%75.1
RS 6M
1%58.2
SMA 50/200
1.05x71.9
EPS Rev 4W
+8.8%94.7
EPS Rev 12W
+8.8%84.4
EPS Improve
-49%9.5
Q Growth
1%39.4

FUNDAMENTALS

Market Cap
$2.2B
P/E (Forward)
14.2x
Gross Margin
75.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AUPH are excluded.

TickerCompanyMkt CapScore
AUPHAurinia Pharmaceuticals Inc.(you)$2.2B96
ABCLAbCellera Biologics Inc.$3.8B30
HELPCybin D/B/A Helus Pharma$744M38
XENEXenon Pharmaceuticals Inc.$3.4B12
BHCBausch Health Companies Inc.$2.4B96
EPRX.TOEupraxia Pharmaceuticals Inc.$452M25
EBM.VEastwood Bio-Medical Canada Inc.$92M48
DHT-UN.TODRI Healthcare Trust$743M93
GUD.TOKnight Therapeutics Inc.$814M82
MSLESatellos Bioscience Inc.$136M17

Peer medians: ROE -31.6% · P/E 19.5x · Gross margin 50.7%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Aurinia Pharmaceuticals Inc. (AUPH): Stock Score Summary

Aurinia Pharmaceuticals Inc. (AUPH) has a MoatMap Score of 96/100 based on Quality (84/100), Value (60/100), and Momentum (61/100) factor scores.

Aurinia Pharmaceuticals Inc. is a Canadian pharmaceutical company primarily focused on developing and commercializing therapies for autoimmune diseases. Its competitive moat is centered around LUPKYNIS (voclosporin), a proprietary drug approved for lupus nephritis, addressing a high unmet medical need and offering a significant market opportunity. Aurinia operates as a commercial-stage biotech, dedicated to expanding the market presence of its specialized therapeutic.

Director dealings

From 2 Jan 2026 to 12 Nov 2026, MoatMap's records hold 2 sales and 6 purchases of Aurinia Pharmaceuticals Inc. (AUPH) shares by its directors. The largest: TANG KEVIN bought 516,439 shares at $13.99 on 27 Feb 2026 (about $7.2M).

  • 10 Sep 2026: Robertson Stephen P. sold 11,939 shares at $15.95 (about $190K)
  • 21 Aug 2026: Robertson Stephen P. sold 20,975 shares at $16.97 (about $356K)
  • 2 Jun 2026: TANG KEVIN bought 206,005 shares at $15.28 (about $3.1M)
  • 1 Jun 2026: TANG KEVIN bought 343,620 shares at $15.28 (about $5.3M)
  • 29 May 2026: TANG KEVIN bought 264,981 shares at $15.31 (about $4.1M)
AUPH insider filings, last 180 days

Key Financial Metrics

Price$16.21
Market Cap$2.2B
P/E (TTM)7.22
P/E (Forward)14.19
Price/Book3.35
Return on Equity61.4%
Return on Invested Capital25.0%
Debt/Equity0.09x
Gross Margin75.7%
Operating Margin42.3%
Revenue Growth13.9%
Free Cash Flow$135M

Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Aurinia Pharmaceuticals Inc.’s (AUPH) MoatMap Score?
The MoatMap Score for Aurinia Pharmaceuticals Inc. (AUPH) is 96/100. It is a composite of Quality (84), Value (60), and Momentum (61), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Aurinia Pharmaceuticals Inc. have an economic moat?
Aurinia Pharmaceuticals Inc. (AUPH) has a Quality factor score of 84/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Aurinia Pharmaceuticals Inc. in?
Aurinia Pharmaceuticals Inc. (AUPH) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).